Anti-S1P/Sphingosine-1-phosphate Reference Antibody (Sonepcizumab, RUO)

Description: Sonepcizumab (BS12052) is a research-grade recombinant antibody targeting S1PSphingosine-1-phosphate. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: General
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: S1PSphingosine-1-phosphate
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: LT1009
Background: Adenosine 3', 5'-cyclic monophosphate (cAMP) is a key second messenger molecule in intracellular signal transduction. Monitoring cAMP levels is one of the most common ways to screen for agonists and antagonists of G protein–coupled receptors(GPCRs). Bioyeargene cAMP ELISA Kit is based on the competition between HRP-labeled cAMP and free cAMP for fixed amounts of mouse monoclonal anti-cAMP antibody(cAMP MAb) binding sites. Because the concentration of the HRP-labeled cAMP is held constant while the concentration of cAMP varies, the amount of HRP-labeled cAMP that is able to bind to the cAMP MAb will be inversely proportional to the concentration of cAMP in the well. This antigen-antibody complex binds to the goat anti-mouse IgG that has been previously attached to the well. The plate is washed to remove any unbound reagents and then developed. The ELISA typically displays an IC50(50% B/B0) of approximately 12 pmol/mL and a detection limit of approximately 0.15 pmol/mL.
References:
1. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy., PMID:31624181
2. Sphingosine-1-phosphate (S1P) in ovarian physiology and disease., PMID:31455516
3. Sphingosine-1-phosphate (S1P) receptors: Promising drug targets for treating bone-related diseases., PMID:32155312
4. Pancreatic Acinar Cells-Derived Sphingosine-1-Phosphate Contributes to Fibrosis of Chronic Pancreatitis via Inducing Autophagy and Activation of Pancreatic Stellate Cells., PMID:37634735
5. Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology., PMID:32278039
6. Sphingosine 1-Phosphate (S1P)/ S1P Receptor Signaling and Mechanotransduction: Implications for Intrinsic Tissue Repair/Regeneration., PMID:31703256
7. Sphingosine 1-phosphate (S1P) receptor modulators as an induction and maintenance therapy for ulcerative colitis: a systematic review and meta-analysis of randomized controlled trials., PMID:38153524
8. S1P (Sphingosine-1-Phosphate)-Induced Vasodilation in Human Resistance Arterioles During Health and Disease., PMID:36070401
9. Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair., PMID:28855094
10. Sphingosine 1-phosphate signalling., PMID:24346695
Note: For research use only. Not suitable for clinical or therapeutic use.